Study of Serum Sclerostin Level in Chronic Kidney Disease

INTRODUCTION: Chronic kidney disease (CKD) is a major public health problem globally. Chronic Kidney Disease is defined as Glomerular Filtration Rate <60ml/min/1.73m2 for a minimum of 3 months irrespective of the cause. The CKD-mineral and bone disorder (CKD-MBD) syndrome is an important complication of kidney diseases and is present early in the evolution of CKD. Sclerostin is a secreted glycoprotein produced primarily by the osteocyte but is also expressed in other tissues, and has anti-anabolic effects on bone formation. AIM OF THE STUDY: To estimate the levels of Serum Sclerostin in patients with CKD and to compare them with healthy normal subjects. MATERIALS AND METHODS: The study was conducted at Thanjavur Medical College Hospital, Thanjavur after getting approval from the ethical committee. 50 patients of known CKD were selected as cases and 50 healthy individuals were selected as controls.Serum Sclerostin was measured by Enzyme Immuno Assay. Blood Urea was measured by Urease-Glutamate Dehydrogenase (GLDH) Method. S.Creatinine was measured by Modified Jaffe’s method. Estimated glomerular filtration rate(eGFR) was calculated using Modification In Diet And Renal Disease(MDRD). S.Phosphorus was measured by Ammonium Molybdate Kinetic Method. RESULTS: Serum Sclerostin concentrations were found to be significantly increased in patients with CKD ((55.1 ± 7.804),) when compared to the control group (mean 31.64 ±5.09). Serum Sclerostin increases as renal function declines and is inversely correlated with Creatinine clearance (r = - 0.4111). Serum creatinine and blood urea were progressively increased in cases than controls and shows positive correlation with serum S clerostin(r = 0.3720 and r = 0.3252). Serum Phosphorus was increased in cases(5.214±0.6217) and it shows positive correlation (r =0.2095) with Serum Sclerostin. CONCLUSION: Serum Sclerostin is a novel biomarker in the prevention of complications such as CKD-MBD in the patients with CKD.